| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 65.398 | 75.175 | 100.308 | 98.516 | 99.820 | 147.177 | 158.213 | 149.591 | 171.891 |
| Total Income - EUR | - | 65.398 | 75.175 | 100.308 | 98.516 | 99.820 | 147.177 | 158.213 | 149.591 | 171.891 |
| Total Expenses - EUR | - | 15.212 | 18.326 | 23.804 | 22.659 | 19.036 | 20.387 | 25.413 | 22.894 | 19.614 |
| Gross Profit/Loss - EUR | - | 50.185 | 56.849 | 76.504 | 75.857 | 80.784 | 126.790 | 132.800 | 126.697 | 152.277 |
| Net Profit/Loss - EUR | - | 48.831 | 56.097 | 75.501 | 74.872 | 79.856 | 125.318 | 131.218 | 125.201 | 147.120 |
| Employees | - | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Endoclinic Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 26 | 0 | 796 | 1.246 | 1.983 | 3.025 | 3.334 | 1.909 | 2.055 |
| Current Assets | - | 50.165 | 56.436 | 74.603 | 74.594 | 78.161 | 122.929 | 128.405 | 124.215 | 147.228 |
| Inventories | - | 0 | 368 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | 11.910 | 4.056 | 6.047 | 23 | 56.496 | 68.618 | 108.926 | 95.635 | 111.557 |
| Cash | - | 38.255 | 52.011 | 68.556 | 74.572 | 21.664 | 54.311 | 19.479 | 28.580 | 35.670 |
| Shareholders Funds | - | 48.875 | 56.150 | 75.552 | 74.922 | 79.906 | 125.367 | 131.267 | 125.250 | 147.168 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 1.330 | 693 | 1.653 | 1.386 | 843 | 1.001 | 1.103 | 1.236 | 2.213 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8623 - 8623" | |||||||||
| CAEN Financial Year |
8623
|
|||||||||
Comments - Endoclinic Srl